Empagliflozin for Obesity and Metabolic Syndrome
This study is looking at how a medicine called empagliflozin might help people with obesity and metabolic syndrome. Empagliflozin is already approved for type 2 diabetes and heart failure. Researchers want to see if it can reduce inflammation (swelling) in fat tissue and improve how blood vessels work. You might be able to join if you are 18 or older and have metabolic syndrome, which means you meet at least three specific health criteria like high blood pressure or high triglycerides. The study will measure changes in fat tissue inflammation and blood vessel function after 12 weeks. The current status of this study is unclear, and it plans to enroll 74 participants.
- Study design
- This is an interventional study that will compare empagliflozin to a placebo (an inactive capsule). It plans to enroll 74 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main measurements for this study are taken at 12 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Mona Mashayekhi, MD, PhD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Adipose tissue macrophages12 weeks
Homeostatic adipose tissue macrophages are quantified
- Flow mediated dilation12 weeks
Brachial artery diameter is measured under basal conditions and during reactive hyperemia
- Monocyte chemoattractant protein-112 weeks
Plasma monocyte chemoattractant protein-1 levels are quantified